Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04715568 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Secondhand Tobacco Smoke and Cardiovascular Disease

StatusRecruiting
PhasePhase 4
Started2021-03-30
View on ClinicalTrials.gov ↗

Amendment history

2026-08-17
Study Status v9
Re-verified, no change to tracked fields
2025-07-21
Study Status v8
Primary completion date2025-12-31→2026-12-31
Completion date2025-12-31→2026-12-31
2024-07-11
4 amendments v4-v7
4 re-verifications since 2021-04-19, no change to tracked fields
2021-04-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2021-02-18
Study Status v2
Start date2021-01-31→2021-03-30
2021-01-19
Study Status, Outcome Measures v1
Secondary endpointsdetails revised at 1 of 15 entries
2021-01-14
Original filing
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Trial Details
NCT Number NCT04715568
Lead Sponsor University of California, San Francisco
Collaborators: Flight Attendant Medical Research Institute
Conditions Cardiovascular Diseases, Hypertension
Enrollment 100 participants
Start Date 2021-03-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-19